Last reviewed · How we verify
Formoterol (Oxis Turbuhaler®)
Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.
Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | Formoterol (Oxis Turbuhaler®) |
|---|---|
| Also known as | Group B patients: Formoterol (Oxis Turbuhaler®)., Oxis Turbuhaler |
| Sponsor | Henan University of Traditional Chinese Medicine |
| Drug class | Long-acting beta-2 agonist (LABA) |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
Formoterol activates beta-2 adrenergic receptors on bronchial smooth muscle cells, triggering a cascade that increases intracellular cAMP levels, leading to smooth muscle relaxation and sustained bronchodilation. The drug has a rapid onset and long duration of action (12 hours), making it suitable for maintenance therapy in obstructive airway diseases. It also has anti-inflammatory properties through effects on mast cells and other immune cells in the airways.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Palpitations
- Muscle cramps
- Nervousness
- Tachycardia
Key clinical trials
- A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS) (PHASE3)
- Activation of Brown Adipose Tissue Thermogenesis in Humans Using Formoterol Fumarate (GB10) (NA)
- Budesonide/Formoterol Turbuhaler® Versus Terbutaline Nebulization as Reliever Therapy in Children With Moderate Asthma Exacerbation (PHASE3)
- Corticosteroids/β2-agonists in Hair in Asthmatic Patients (CorticHair) (NA)
- Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing. (PHASE3)
- Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD) (PHASE3)
- A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos) (PHASE3)
- Effect of Symbicort ® on GR in Sputum in COPD (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: